Status:
COMPLETED
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Lead Sponsor:
ETOP IBCSG Partners Foundation
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Pleural Mesothelioma Malignant Advanced
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesotheliom...
Detailed Description
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is almost always caused by...
Eligibility Criteria
Inclusion
- Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible)
- Not amenable for radical surgery based on local standards
- Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1
- Availability of tumour tissue for translational research
- Age \>18 years
- Performance Status 0-1
- Life expectancy \>3 months
- Adequate haematological, renal and liver function
- Completed baseline quality of life (QoL) questionnaire
- Women of childbearing potential and sexually active men must agree to use highly effective contraception
- Able to understand and give written informed consent and comply with trial procedures
Exclusion
- Prior treatment for malignant pleural mesothelioma. Prior radiotherapy for symptom control is allowed, but the irradiated lesion cannot be used as target lesion. If the patient has another target lesion, the patient is eligible.
- Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment.
- Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment.
- Previous allogeneic tissue/solid organ transplant
- Live vaccines within 4 weeks prior to first dose of protocol treatment
- Inadequately controlled hypertension
- Prior history of hypertensive crisis or hypertensive encephalopathy
- Significant vascular disease within 6 months prior to randomisation
- History of haemoptysis
- Evidence of bleeding diathesis or coagulopathy
- Active autoimmune disease that has required systemic treatment in past 2 years
- History of active diverticulitis
- Previous treatment with atezolizumab and/or bevacizumab or parallel participation in other interventional clinical trial with atezolizumab and/or bevacizumab.
Key Trial Info
Start Date :
April 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2024
Estimated Enrollment :
401 Patients enrolled
Trial Details
Trial ID
NCT03762018
Start Date
April 30 2019
End Date
November 18 2024
Last Update
June 4 2025
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Leuven
Leuven, Belgium
2
CHU Liege
Liège, Belgium
3
Unicancer - Institut Bergonie
Bordeaux, France
4
Caen- CHU
Caen, France